Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Nimbus rakes in $210 million in financing for small molecules

by Gina Vitale
September 9, 2023 | A version of this story appeared in Volume 101, Issue 30

 

Nimbus Therapeutics, a structure-based drug discovery firm that designs small-molecule therapeutics using computational chemistry, has closed a $210 million private financing round. Google Ventures, a new investor, co-led the round, which also saw participation from existing investors, including Gates Frontier, Pfizer Ventures, and RA Capital Management. Nimbus has one drug candidate in a clinical trial and says that this funding will allow it to advance several preclinical programs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.